Celebrating 25 Years of Scoop
Special: Up To 25% Off Scoop Pro Learn More
Parliament

Gordon Campbell | Parliament TV | Parliament Today | Video | Questions Of the Day | Search

 

Agreement Advanced To Purchase Up To 5 Million COVID-19 Vaccines

Hon Megan Woods 
Minister of Research, Science and Innovation  

The Government has confirmed an in-principle agreement to purchase up to 5 million COVID-19 vaccines – enough for 5 million people – from Janssen Pharmaceutica, subject to the vaccine successfully completing clinical trials and passing regulatory approvals in New Zealand, says Research, Science and Innovation Minister Megan Woods.

“This agreement forms part of our portfolio approach to ensure that we have the ability to access a range of vaccine options, if and when a suitable vaccine is developed and approved,” says Megan Woods.

“It is an initial agreement with Janssen Pharmaceutica, and we expect a formal advance purchase agreement to be finalised in coming weeks.

“The agreement with Janssen would see the first doses – up to 2 million – delivered from the third quarter of 2021. We have the option to purchase up to 3 million additional doses, which would be delivered throughout 2022.

“A key point of difference for the Janssen vaccine is that it’s likely to be a single-dose vaccine and is compatible with standard vaccine distribution channels, so it may potentially be more efficient to administer.”

Megan Woods said Janssen, along with its parent company Johnson & Johnson, have a very strong track record producing safe and effective pharmaceutical products for use globally and in New Zealand.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

“This gives us confidence in their ability to develop, manufacture and deliver a safe and effective vaccine,” Megan Woods said

This announcement follows the Government’s recent agreement to purchase 1.5 million doses of vaccine – enough for 750,000 people – from Pfizer and BioNTech, and works alongside other aspects of the COVID-19 Vaccine Strategy, including membership of the global COVAX Facility.

Megan Woods said negotiations with other pharmaceutical companies are progressing well.

“The COVID-19 Vaccine Strategy Taskforce are working to ensure that additional agreements are in place to complete the vaccine portfolio. Our main priority is to make sure New Zealand and our Pacific neighbours have access to safe and effective vaccines.

The Ministry of Health is preparing for a range of vaccine scenarios and how best to sequence the delivery of vaccines once supply becomes available. Three broad considerations are being explored:

  • Those at risk of contracting COVID-19
  • Those at risk of spreading COVID-19
  • Those at risk of increased morbidity and mortality associated with COVID-19.

Ensuring equity of outcomes, including protection for Māori, Pacific peoples and our most vulnerable population groups, such as older people, disabled people, health workers, essential workers and border staff are some of our primary considerations in the availability of vaccines.

NOTES FOR EDITORS:

  • Medsafe has agreed to allow pharmaceutical companies to make rolling applications for their COVID-19 vaccines, which means they may submit their data as it is completed and ready for assessment.
  • Timing around Medsafe’s approval process depends on many factors, such as the data that companies provide and whether it meets internationally agreed criteria for safety and efficacy.
  • While Medsafe will be streamlining its assessment processes and prioritising the assessment of COVID-19 vaccines over other pharmaceuticals to obtain a vaccine more quickly, there will be no compromise on the integrity of the process or on the safety of the vaccine.
  • Safety will always be the priority and Medsafe will not be rushed into accepting the first vaccine that shows promise without the vaccine meeting internationally agreed criteria for safety, efficacy and quality. This includes data from well-designed clinical trials.

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Parliament Headlines | Politics Headlines | Regional Headlines

 
 
 
 
 
 
 

LATEST HEADLINES

  • PARLIAMENT
  • POLITICS
  • REGIONAL
 
 

InfoPages News Channels


 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.